GSKBritish GlaxoSmithKline plc (GSK) has entered a US$745m licensing agreement with Empirico Inc for EMP-012, a first-in-class siRNA candidate for COPD. EMP-012 targets the underserved non-type 2 inflammation market segment valued at US$600–700bn.
Tag Archive for: COPD
Maxwell Hamilton - wikipedia.orgFollowing Merck Sharp & Dohme (MSD)’s US$10bn acquisition of Verona Pharma and its potential COPD blockbuster Ohtuvayre®, GlaxoSmithKline (GSK) has secured a US$12bn deal for another PDE3/PDE4 inhibitor.
French Sanofi SA’s second Phase III trial of duplimab demonstrated a 34% reduction in exacerbations and significant lung function improvements.
C4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m.
EpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395